Clinical Guidelines
FDA & Government News

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine (AVD) was approved today for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical ...

Share

  • 1

    Nivolumab approved with AVD for untreated Hodgkin lymphoma (12+).

  • 2

    Study CA209-8UT had 994 participants, showing improved progression-free survival.

  • 3

    Nivolumab dosing: 240 mg or 3 mg/kg every 28 days for 6 cycles.

  • 4

    Serious adverse reactions in 39% of nivolumab patients.

  • 5

    Collaborative review under Project Orbis involving multiple international agencies.

Original Source(s)

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

  • by The ASCO Post Staff

  • March 20, 2026

Related Content

MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma

For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv pl...

Coalition urges Congress to boost CDC tobacco prevention funding

The ADA joined a coalition urging Congress to provide $310 million for tobacco prevention and cessation programs at the CDC.

Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

Preclinical results and AI integration support progress toward regulatory submission